Background: Cepharanthine (CEP) is a biscoclaurine alkaloid extracted from Stephania cepharantha and has been shown to have an anti-tumour effect on different types of cancers. However, the anti-cancer effect of CEP on human breast cancer cells is still unclear. Methods: We used MTT, clone formation, in vitro scratch, invasion and migration assays to confirm the inhibitory role of CEP on the proliferation of breast cancer cells. Flow cytometry, plasmid construction and western blot analysis were used to study the detailed mechanisms. Results: Our study showed that CEP could inhibit cell proliferation by inducing autophagy, apoptosis, and G0/G1 cell cycle arrest of breast cancer cells. Furthermore, we found that CEP induced autophagy and apoptosis by inhibiting the AKT/mTOR signalling pathway. Conclusion: We found that CEP could inhibit growth and motility of MCF-7 and MDA-MB-231 breast cancer cell. Our study revealed an anti-tumour effect of CEP on breast cancer cells and suggests that CEP could be a potential new clinical therapy for breast cancer.
Introduction
Breast cancer is one of the most common types of malignant tumour, and in recent years, it has been the second leading cause of death among females around the world [1] . In 2015, approximately 4,292,000 Chinese women were diagnosed with breast cancer, and 2,814,000 died from this disease [2] . The standard treatments for breast cancer include surgical operation, chemotherapy, radiotherapy, endocrine therapy, target therapy and other supplement therapies. However, most of these traditional treatments cause side effects that affect the quality of life of patients [3] . It is therefore necessary to explore new therapies for breast cancer patients, that will improve their prognosis and quality of life.
for 24, 48 , and 72 h. Then, 20 µL of MTT (5 mg/mL) was added to each well, and the cells were incubated for another 4 h at 37°C. After removal of MTT, 100 μL of DMSO was added to each well, and the plate was gently shaken for 10 min at room temperature. The absorbance was measured with the Microplate Reader (Bio-Rad, Hercules, CA, USA) at 490 nm. All experiments were repeated at least three times.
Colony forming assay MCF-7 and MDA-MB-231 cells were treated with different concentrations of CEP for 24 h. Nextthe cells were seeded in 6-cm Petri dishes (1500 cells per dish) and cultured in complete medium for 14 days. The medium was refreshed every three days. Thereafter, the cells were washed with phosphate-buffered saline (PBS), fixed with paraformaldehyde and stained with 0.5% crystal violet. Images of colonies were taken using an Olympus digital camera (Olympus, Tokyo, Japan).
In vitro scratch assay
To evaluate how CEP affect migration ability, a scratch assay was performed with the MCF-7 and MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells were harvested by trypsinization and were seeded in 24-well plates at a density of 3×10 5 or 2×10
5
, respectively. Cells, at confluency, were grown in complete medium for 24 h. After then the cells were scraped with p20 pipette tips to create a straight-line "scratch". Reference points near the "scratch" were marked to guarantee the same area of image acquisition. The cells were treated with different concentrations of CEP (5 µM for MCF-7, 4 µM for MDA-MB-231), and images were taken at intervals of 12 h and 24 h. The images were analysed quantitatively by Image-Pro Plus.
Invasion and migration assays
The invasion assay was performed using the Transwell system (Corning Costar, Lowell, MA, USA) to detect any CEP-induced changes to the invasiveness of MDA-MB-231 cells. MDA-MB-231 cells (1×10 5 ) were suspended in serum-free medium and then added to the upper inserts, and 700 µL of complete medium with 20% FBS was added to the lower well of each chamber. After incubation for 24 h, the wells were collected. The migration assay was performed in the same way as the invasion assay above except that the membrane was not coated with Matrigel. MDA-MB-231 and MCF-7 cells (1×10 5 ) were added to the upper wells. The cells from the appropriate wells were collected after 15 h (MDA-MB-231) or 48 h (MCF-7). The total number of cells invading and adhering to the lower surface was acquired with an Olympus light microscope (Tokyo, Japan).
Cell-cycle analysis

3×10
5 cells/well was seeded into a 6-cm Petri dish. After 24 h incubation, the cells were treated with CEP for 24 h or 48 h, then collected and fixed with 75% cold ethanol (1mL PBS and 3mL absolute ethanol) at -20°C overnight. After that, the DNA of cells was incubated with 200 μL RNase A (1 mg/mL) and 500 μL propidium iodide (PI, 100 μg/mL) for 30 min at room temperature in the dark and analysed using the FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). The data were analysed with ModFitLT V2.0 software (Becton Dickinson, Franklin Lakes, NJ, USA).
Identification of apoptosis by PI-Annexin-V staining
MCF-7 and MDA-MB-231 cells were cultured in 6-cm Petri dishes for 24 h prior to treatment. The cells were treated with different concentrations of CEP for 48 h and were harvested by trypsinization with 0.1% trypsin. Then, cells were stained with 5 μL Annexin V-FITC and 5 μL propidium iodide (PI) (20 μg/mL) and were incubated for 15 min in the dark at room temperature. Then, the cells were incubated with 200 μL RNase A (1 mg/mL) for 30 min at room temperature in the dark. The apoptotic cells were detected using a FACScan flow cytometer, and the data were analysed using WinMDIV2.9 software (The Scripps Research Institute, San Diego, CA, USA).
Immunocytochemical analysis
Cells were seeded in 24-well plates on a coverslip and treated with CEP for 48 h. Then, cells were fixed with 4% paraformaldehyde and stained with Acridine Orange (1 µg/mL). After that, the coverslips were fixed on the glass slides with anti-fading medium (Beyotime Institute of Biotechnology, Jiangsu, China). The slides were sealed by neutral resin and observed under a fluorescence microscope (Olympus, Tokyo, Japan). The images were analysed using ImageJ software. 
Flow cytometry analysis of acidic vesicular organelles (AVO)
To evaluate the change in the number of AVOs in cells treated with CEP, cells were treated with different concentrations of CEP for 48 h; then, cells were stained with Acridine orange (1 μg/mL) at room temperature for 15 min in the dark. The cells were washed immediately three times with PBS and were analysed in a FACScan flow cytometer. The data were analysed using BD Cell Quest software.
Western blot analysis
Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer and PMSF (Biocolors, Shanghai, China) and quantified using the BCA protein concentration assay kit (Merck, Darmstadt, Germany). Fifty micrograms of proteins were separated by 10% SDS-PAGE and were electro-blotted onto a PVDF membrane using a semidry blotting apparatus (Bio-Rad, Hercules, CA, USA). After blocking with 5% non-fat milk, the membranes were incubated with primary antibodies overnight at 4°C. The next day, the membranes were labelled with secondary antibody, and signals were detected using a Luminescent Image analyzer (GE Healthcare Bio-Sciences, Uppsala, Sweden). β-actin was used as the endogenous control.
Statistical analysis
The results were analysed using SPSS software (SPSS, Chicago, IL, USA). Two-tailed Student's t-tests and one-way ANOVAs were performed to determine significance. Each experiment was performed three times, and differences were considered significant when p-values <0.05.
Results
CEP inhibited the proliferation of breast cancer cells
We used MTT and clone formation assays to demonstrate the effect of CEP on the proliferation of breast cancer cells. As shown in Table 1 . We demonstrated that MDA-MB-231 cells were more sensitive than MCF-7 cells to CEP-induced inhibition of proliferation. Furthermore, CEP inhibited the proliferation of both MCF-7 and MDA-MB-231 breast cancer cells in dose-and time-dependent manners. In the MCF-7 cells, a sharp decrease in cell viability was observed with 10 µM CEP that was independent of the treatment time (p<0.01). However, a cytotoxic effect was observed in MDA-MB-231 cells treated with 6 µM CEP for 24 h and 48 h. The clone formation assay was used to evaluate the clone formation ability of MCF-7 and MDA-MB-231 cells. As shown in Fig. 1D , E, with increasing CEP concentration, the clone formation ability decreased in both cell lines.
CEP inhibited the motility of breast cancer cells
As shown in Fig. 2 , we detected the effect of CEP on motility of breast cancer cells by using scratch, migration and invasion assays. The assays revealed similar results. Compared with untreated cells, MCF-7 and MDA-MB-231 cells treated with CEP exhibited inhibited migration ( Fig. 2A, B) . Fig. 2C revealed that the number of invading MDA-MB-231 cells in the 
CEP induced cell apoptosis in breast cancer cells
The effect of CEP on the induction of cell apoptosis in breast cancer cells was measured by PI-Annexin V double staining. As shown in (Fig. 4B) . These data revealed that CEP caused apoptosis in both breast cancer cell lines.
The mechanisms of CEP-induced apoptosis were determined by western blot. As shown in Fig. 4C , D, the expression of BCL-2, Bax, Cleaved-caspase-3 and Cleaved-caspase-9 were altered significantly in a dose-and time-dependent manner in MCF-7 and MDA-MB-231 cells. Western blot analysis revealed that P62, LC3B, Beclin-1, and ATG-7 protein levels changed significantly with CEP treatment. (E) Effect of autophagy inhibitor chloroquine (CQ), and (F) autophagy inducer rapamycin (Rapa) on LC3B and P62 expression levels in breast cancer. Cells were exposed from 24 h to 72 h to 20 µM CQ or to 2 µg/mL Rapa; then, the LC3B and P62 protein levels were detected by western blotting. ** p < 0.01; *** p < 0.001 vs. the control group, the results are representative of three independent experiments. undergoing autophagy. We observed that CEP enhanced the induction of autophagy in MCF-7 (Fig. 5A ) and MDA-MB-231 (Fig. 5B ) cells when the cells were treated with various concentrations of CEP for 48 h.
To further investigate the mechanism involved in CEP-mediated cell autophagy, the proteins related to cell autophagy were measured by western blot. As shown in Fig. 5C , D, the levels of LC3B, Beclin1, and ATG-7 were increased, and the level of P62 was decreased significantly in MCF-7 and MDA-MB-231 cells treated with CEP. These data demonstrated The protein levels of AKT, BCL-2, Bax, LC3B, Beclin-1, Cyclin D1, and CDK4 were examined using western blot. * p < 0.05; ** p < 0.01. The experiments were performed in triplicate, and data are presented as the mean ± SD of three separate experiments.
that CEP induced cell autophagy in a dose-and time-dependent manner in both breast cancer cell lines.
CEP induced autophagy-associated cell death in breast cancer cells
To investigate whether the induction of autophagy contributed to CEP-induced cell death, we treated cells with CQ (20 µM) and 3-MA (4 µM) for 1 h before treatment with CEP. Chloroquine (CQ) inhibits lysosome acidification and degradation, and 3-methyladenine (3-MA) is an inhibitor of autophagosome formation [27] . The cytotoxic effect of CEP combined with 3-MA and CQ treatment was measured by MTT assay. As shown in Fig. 6A , C, co-treatment with either CQ or 3-MA significantly decreased the CEP-induced cell death in MCF-7 cells at 48 h and 72 h. The results observed in MDA-MB-231 cells revealed that co-treatment with either CQ or 3-MA decreased CEP-induced cell death in a time-dependent manner (Fig. 6B, D) . LC3B and P62 are the most common autophagic markers. Cells were exposed to the autophagy inhibitor CQ and the autophagy inducer rapamycin (Rapa) from 24 h to 72 h. The results revealed that CQ could increase LC3B and P62 (Fig. 5E ) in breast cancer cells. However, the P62 level was decreased, and LC3B was increased after Rapa treatment (Fig. 5F ). These data suggest that CEP induced autophagy cell death in both breast cancer cell lines.
CEP regulated AKT/mTOR signalling pathway in breast cancer cells
To further elucidate the potential mechanisms of CEP on apoptosis and autophagy, we investigated whether the AKT/mTOR pathway was involved in CEP-induced apoptosis and autophagy in MCF-7 and MDA-MB-231 cells. As shown in Fig. 6E , phosphorylated AKT (Ser473) and phosphorylated mTOR were decreased, and the mTOR downstream targets p70S6K (Ser371), p-S6 (Ser240/244) and p-4E-BP1 (Thr70) were reduced significantly after treatment with CEP. AKT can induce changes in cell cycle distribution [28] . GSK3β is a downstream effector of AKT, and as an upstream regulator of Cyclin D1 [29] . Compared with the control group, the level of p-GSK3β (Ser21/9) was decreased in CEP-treated cells (Fig.  6E) .
CEP inhibited AKT in breast cancer cells
To further confirm whether CEP-induced apoptosis and autophagy is AKT-independent, we demonstrated the effect of AKT expression on breast cancer cells using flow cytometry analysis and western blot. As shown in Fig. 7A , B, pcDNA3.1-AKT transfection together with CEP treatment altered the number of apoptotic and autophagic cells when compared to pcDNA3.1-AKT transfection without CEP treatment in MCF-7 and MDA-MB-231 cells. These results revealed that CEP-induced apoptosis and autophagy might be Akt-specific or Aktdependent in breast cancer cells. In Fig. 7C , AKT overexpression downregulated Bax, Beclin1, and LC3B, upregulated BCL-2 and partially reversed the suppression of Cyclin D1 and CDK4 protein levels. However, compared with AKT overexpression alone, Bax, Beclin1, and LC3B were increased, and BCL-2, CyclinD1 and CDK4 were decreased in both AKT-transfected breast cancer cell lines treated with CEP.
Discussion
TCM has been confirmed to be effective in the treatment of a number of tumours [30, 31] . CEP is a biscoclaurine alkaloid extracted from Stephania cepharantha [17] . In a previous clinical study, CEP had effects on adjuvant chemotherapy-induced bone marrow suppression, leukopenia and thrombocytopenia in breast cancer patients [32, 33] ; however, the anti-tumour effect of CEP on breast cancer is unclear.
In our study, we found that CEP could inhibit cell proliferation and motility. MTT and clone formation assays showed that CEP inhibited cell proliferation in a time-and dosedependent manner in MCF-7 and MDA-MB-231 cells. After treatment with CEP, we observed reductions in cell motility, which were measured by scratch, migration and invasion assays. Previous studies have shown that CEP induces apoptosis in myeloma cells [18] and hepatocellular carcinoma [34] . However, whether CEP can induce apoptosis in breast cancer cells is unknown. Our finding demonstrated that CEP induces cell apoptosis in two breast cancer cell lines. The underlying mechanism of CEP-induced apoptosis in breast cancer cells was assessed by western blot. The mitochondrial pathway is an important mediator of cell apoptosis, and the BCL-2 family has an important role in the mitochondrial pathway [35] . BCL-2 family members include anti-apoptotic BCL-2 protein and pro-apoptotic Bax protein [36] . Bax-induced growth arrest is associated with the release of cytochrome c from mitochondria, which is blocked by BCL-2 [37] . In intrinsic apoptotic stimulation, cytochrome c is released into the cytosol, where it triggers the formation of the apoptosome, which activates caspase-9 [38] . The caspase-9/apoptosome complex then targets and activates the effector caspase 3 [39] . In our study, CEP induced apoptosis by increasing the Bax/BCL-2 ratio and by activating Cleaved-caspase-3 and Cleaved-caspase-9, as measured by western blot. Furthermore, our results showed that Z-VAD-FMK blocked CEP-induced apoptosis, as revealed by the PI-Annexin V assay. The results demonstrated that CEP could induce apoptosis by activating the intrinsic mitochondria-mediated caspase pathway.
In recent years, it has been reported that programmed cell death (PCD) is not confined to apoptosis (type-I PCD) and that cells use different pathways for active self-destruction. Another important programmed cell death pathway is autophagic cell death (type-II PCD) [40] . A previous study has demonstrated that autophagy can improve anticancer therapy [41] . During the autophagy process, portions of the cytoplasm are sequestered within doublemembrane vesicles known as autophagy vacuoles, which then fuse with lysosomes to form single-membrane autophagolysosomes [42] . LC3 is important for autophagosome formation and function, and it is conjugated by Atg7. P62 is incorporated in completed autophagosomes and degraded in autolysosomes [43, 44] . In our study, we investigated CEP-induced autophagy by using an acidic vesicular organelle (AVO) staining assay and flow cytometry analysis. Using western blot analysis, we examined LC3B, Beclin1, ATG-7, and P62 protein levels after treatment with CEP. To further investigate whether CEP-induced autophagy could affect its antitumour activity, we conducted two combination experiments with autophagy inhibitors 3-MA and CQ and then examined cell viability via the MTT assay. Furthermore, we detected the protein levels of LC3B and P62 in MCF-7 and MDA-MB-231 cells after treatment with CQ or Rapa. These results suggested that CEP induced autophagy in both breast cancer cell lines.
It has been reported that CEP can induce G0/G1 cell cycle arrest in myeloma cells [18] . In an earlier study, it was demonstrated that P21 is a cyclin-dependent kinase inhibitor [45] . CyclinD1 is a key regulator in G1 progression, and the cyclin D/Cdk complexes could phosphorylate Rb directly [46, 47] . GSK3β is a downstream effector of AKT and an upstream regulator of Cyclin D1 [29] . In our study, we investigated CEP-induced cell cycle arrest by flow cytometry analysis. Furthermore, the underlying mechanism of G0/G1 arrest was determined by western blot. Our results indicated that CEP could induce cell cycle arrest in the G0/G1 phase, and CEP-induced G0/G1 arrest might occur through inhibition of the AKT/ GSK3β/Cyclin D1/p-Rb pathway.
A previous study has shown that CEP can induce apoptosis in hepatocellular cancer cells and in leukaemia cells via downregulation of Akt [34] . AKT signalling has an important role in the regulation of cell proliferation, angiogenesis, migration and invasion [48] . Numerous studies revealed that mTOR kinase could suppress autophagy and apoptosis [49] . Our results demonstrated that phosphorylated AKT and phosphorylated mTOR were decreased in both breast cancer cell lines after CEP treatment. These data demonstrated that CEP might induce apoptosis and autophagy in breast cancer cells by inhibiting the AKT/ mTOR signalling pathway. In our study, overexpression of AKT could induce apoptosis and autophagy following CEP treatment, as measured by flow cytometry analysis and western blot. Furthermore, the expression level of Bax was upregulated and the suppression of AKT/BCL-2/CyclinD1/CDK4 was partially reversed after overexpression of AKT alone and in combination with CEP treatment. These results indicated that there are likely other functional mediators of CEP-induced apoptosis and autophagy in breast cancer cells.
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